Literature DB >> 3190431

Effects of cardiopulmonary bypass on pulmonary leukostasis and complement activation.

R J Howard1, C Crain, D A Franzini, C I Hood, T E Hugli.   

Abstract

We measured white blood cell counts and complement component (C3a, C4a, and C5a) and prostacyclin levels, and studied lung biopsy specimens, in 16 patients undergoing cardiopulmonary bypass and compared them with four patients undergoing other pulmonary procedures. Bypass caused no significant elevation in peripheral venous white blood cell counts. Higher counts were present in the right atrium compared with the left atrium. Patients who underwent bypass had elevated complement component and prostacyclin concentrations before operation and these levels increased further during operation. Trapping of polymorphonuclear leukocytes occurred in pulmonary alveolar capillaries and venules after bypass. We conclude that bypass activates complement components primarily of the alternative pathway and leads to increased blood prostacyclin levels. These changes are accompanied by polymorphonuclear leukocyte accumulation in the lungs and may be important in initiation of the adult respiratory distress syndrome in these patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3190431     DOI: 10.1001/archsurg.1988.01400360066010

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  9 in total

1.  Superior biocompatibility of heparin-bonded circuits in pediatric cardiopulmonary bypass.

Authors:  T Ozawa; K Yoshihara; N Koyama; S Yamazaki; Y Takanashi
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1999-12

2.  Inadequate cytoplasmatic calcium signals in alveolar macrophages after cardiac surgery.

Authors:  Katharina Berger; Michael Sander; Anke Kohlar; Christian Meisel; Wolfgang Konertz; Thomas Volk
Journal:  Inflamm Res       Date:  2010-04-02       Impact factor: 4.575

3.  Changes in neutrophil CD11b/CD18 and L-selectin expression and release of interleukin 8 and elastase in paediatric cardiopulmonary bypass.

Authors:  A Finn; N Moat; N Rebuck; N Klein; S Strobel; M Elliott
Journal:  Agents Actions       Date:  1993

4.  Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage.

Authors:  M Fung; M Lu; H Fure; W Sun; C Sun; N Y Shi; Y Dou; J Su; X Swanson; T E Mollnes
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

5.  Intravenous loading of nitroglycerin during rewarming of cardiopulmonary bypass improves metabolic homeostasis in cardiac surgery: a retrospective analysis.

Authors:  Ying-Hsuan Tai; Kuang-Yi Chang; Shu-Wei Liao; Kwei-Chun Chung; Chun-Che Shih; Shung-Tai Ho; Chih-Cherng Lu; Mei-Yung Tsou
Journal:  J Anesth       Date:  2016-06-22       Impact factor: 2.078

6.  Effect of PAF on polyrnorphonuclear leucocyte plasma membrane polarity: a fluorescence study.

Authors:  A Kantar; P L Giorgi; R Fiorini
Journal:  Mediators Inflamm       Date:  1993       Impact factor: 4.711

7.  Oral neutrophils are an independent marker of the systemic inflammatory response after cardiac bypass.

Authors:  Mary Elizabeth Wilcox; Emmanuel Charbonney; Pablo Perez d'Empaire; Abhijit Duggal; Ruxandra Pinto; Ashkan Javid; Claudia Dos Santos; Gordon David Rubenfeld; Susan Sutherland; Wayne Conrad Liles; Michael Glogauer
Journal:  J Inflamm (Lond)       Date:  2014-10-18       Impact factor: 4.981

8.  Preoperative oral pentoxifylline in case of coronary artery bypass grafting with left ventricular dysfunction (ejection fraction equal to/less than 30%).

Authors:  Soheil Mansourian; Payvand Bina; Arezoo Fehri; Abbas Ali Karimi; Mohammad Ali Boroumand; Kyomars Abbasi
Journal:  Anatol J Cardiol       Date:  2014-12-31       Impact factor: 1.596

9.  NPC 15669 blocks neutrophil CD18 increase and lung injury during cardiopulmonary bypass in pigs.

Authors:  J M Bator; A M Gillinov; K J Zehr; J M Redmond; I C Wilson; A Herskowitz; J R Connor; R M Burch; D E Cameron
Journal:  Mediators Inflamm       Date:  1993       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.